Why should pharmacies beware offshore payment brokers?

What is the ecosystem, and how does it identify prospects?

Beneath the payments market this cluster has mapped sits a reselling layer: brokers and agent networks that place merchants with acquiring banks abroad. The chains often run from broker to master agent to intermediate entity to an acquirer in a jurisdiction selected for appetite rather than proximity. The layer is not hidden — it advertises extensively and effectively. It finds prospects in two places.

The first is search. Content operations rank against every phrase a concerned founder is likely to type: pharmacy merchant accounts, high-risk pharmacy processing, declined by a mainstream processor. The result is that the ecosystem's marketing is often the first authoritative-looking answer a new operator meets. That is among the reasons this cluster exists.

The second is the account limitation itself. Terminated and limited merchants are visible to the ecosystem through its own channels. The approach that arrives days after a limitation — sympathetic, urgent and solution-shaped — is distribution, not coincidence. It is engineered for the single week in which a rational operator might sign almost anything. The account-loss guide anticipated it. This analysis sets out at length why the answer is no.

How does the chain operate?

Understanding the structure is the strongest protection, so look at the mechanism without its sales presentation. The person making contact is almost never a bank. They are an agent, or an agent of an agent, in a reselling hierarchy where each layer earns residuals — a share of every transaction the merchant will ever process, paid down the chain for as long as the account survives.

That single feature explains the layer's behaviour better than any theory of conspiracy. Everyone between the merchant and the acquirer is paid on placement and volume. Nobody in the chain is paid for declining. And the diligence a bank would conduct is precisely the friction the model exists to remove.

It also explains the pricing opacity. The merchant's rate must pay every participant in the hierarchy, which is where the discretionary reserves and elaborate fee schedules come from. And it explains the contractual structure. The merchant signs with the broker or an intermediate entity because the chain's economics depend on owning the merchant relationship — and on being able to move an account between acquirers, without the merchant's involvement, when a bank's appetite or licence expires.

Settlement then flows back down the same chain, pausing wherever any layer hits a cash-flow difficulty. That is why funds held offshore often have no single party capable even of locating them. None of this is exotic finance. It is a commission structure using a bank's vocabulary — and once you have seen it, you will recognise it in the next approach you receive.

What do the standard propositions decode to?

The copy is remarkably consistent across the layer. Each proposition decodes to a structure.

"Guaranteed approval" means underwriting will not happen. The price of admission is that nobody is examined — including the merchants whose proximity the applicant inherits. "We work with forty-plus acquiring banks worldwide" means the application will be circulated down a chain until an institution with appetite accepts it. The merchant will neither select, meet nor contract directly with the party holding its funds.

"Offshore merchant account with international banking" means settlement sits under foreign law, reached through intermediaries, outside the FCA's supervision and the ombudsman's jurisdiction. Recourse is determined by leverage rather than rights. "Crypto-friendly settlement" means value can move in forms designed to resist tracing.

"No need to worry about card scheme registration" means the registration and certification obligations this cluster has documented will become somebody's problem later — and the somebody runs a pharmacy. And "we understand pharmacy" means the vertical is named because the vertical converts, for reasons the next section makes uncomfortable.

None of these sentences is unlawful to write. Together they describe a product whose value lies in the absence of enquiry. A legitimate pharmacy is a business with good answers. That is the whole mismatch.

Which clientele does it serve?

What does it cost a legitimate pharmacy?

Priced honestly, the arrangement fails on its own terms before ethical considerations arise.

Recourse. The UK layer this cluster has documented — FCA-supervised counterparties, ombudsman access for eligible smaller businesses, enforceable domestic terms — is precisely what offshore structures remove. A limitation that is survivable onshore becomes, offshore, a negotiation with parties who owe process in no forum the merchant can reach.

Settlement risk. The merchant's float sits at the far end of a chain in which any link — broker, intermediate entity, acquirer or correspondent bank — can pause it. Funds held in this layer tend to move from delayed to irrecoverable without any document recording the transition.

Actual pricing. Headline rates conceal rolling reserves adjusted at discretion, settlement in currencies and rhythms that add spread, and fee schedules that reward skipping the effective-rate arithmetic the criteria guide sets out.

Diligence contamination. Every later underwriter, bank, investor and purchaser examines processing history. An offshore high-risk period reads one way: a merchant that could not, or would not, pass onshore examination. The signal outlasts the arrangement by years.

Regulatory perception. A GPhC-registered business routing patient payments through opaque foreign structures has voluntarily built the financial architecture of the operations the MHRA prosecutes. Explaining the resemblance becomes a permanent feature of its affairs.

Sum those lines and the offshore account is expensive even while it works. And it works until the day it is the only thing that matters — at which point it stops.

What is the domestic banking dimension?

One cost line sits closer to home than the acquiring itself: the merchant's own UK business bank. Settlements arriving from unfamiliar acquirers via intermediate entities are precisely the pattern domestic banks' monitoring exists to query. A pharmacy receiving them should expect source-of-funds enquiries and enhanced review. In the current environment of wholesale de-risking, it should also expect the genuine possibility that a compliance function resolves its discomfort by closing the account rather than understanding it — a serious event with no appeal, arriving by letter.

The same flows complicate everything else that examines bank statements. That means the accountant's audit trail, a lender's affordability assessment, and the acquirer applications this cluster recommends keeping uncomplicated. It also means any future diligence in which a purchaser's adviser traces revenue to its source and finds a jurisdiction requiring explanation.

A pharmacy's finances should be unremarkable by design. The offshore arrangement makes them interesting to precisely the audiences whose interest is least desirable. And unlike the acquiring risk, this exposure operates whether or not the offshore account ever malfunctions. The route by which money comes home is part of the product — and it is the part the proposition omits.

What are the indicators?

To a reader who knows the indicators, the layer identifies itself within a single email. Most of the tells appear before any contract does.

Unsolicited contact within days of a limitation. Guaranteed or hundred-per-cent approval language in any form. Reluctance, when asked directly, to name the actual acquiring bank and the jurisdiction of settlement before signature. A contract with the broker or an intermediate entity rather than with the acquirer. Advice to adjust the website, soften the descriptors or describe the business as wellness — the same instruction the high-risk analysis identified as the limitation scenario offered as onboarding. Upfront and application fees scaled to urgency. Settlement offered or encouraged in crypto. And marketing that addresses the vertical warmly while asking nothing about registration. A counterparty uninterested in a GPhC number has told you what its diligence consists of.

Any single indicator justifies a short reply. Two or more require no reply at all.

Why is it never necessary?

The determining fact is the one this cluster spent five articles establishing: the legitimate path exists at every tier. Consider a registered UK pharmacy holding the underwriting file, with certification in progress and access to the honest routes described in the named comparison — pharmacy-accepting PSPs, traditional acquirers, onshore FCA-supervised specialists for harder mixes, and rebuild routes after terminations handled transparently. That pharmacy has an onshore answer for every legitimate configuration of products, volumes and history.

The only pharmacy without an onshore answer is one whose model cannot survive examination. That pharmacy's problem is the model, not the acquiring market. Fixing the model is cheaper, in every currency, than exporting the problem to a jurisdiction that will hold the merchant's funds while it discovers why. Offshore acquiring solves a problem a legitimate operator does not have, at prices only an illegitimate one should be willing to pay. No third category of customer exists. That is the whole warning.

What should an operator already inside do?

Some readers are inside one of these arrangements, having boarded during a difficult week or acquired it with a business. The exit is a sequence, not a confession.

Board onshore first, through this cluster's honest routes, disclosing the offshore period accurately and briefly. Underwriters rate disclosed history handled well far above discovered history explained late. Then migrate deliberately. Direct new volume to the onshore rail immediately. Re-paper recurring mandates through the token-portability and re-authorisation approach the criteria guide sets out. And reduce the float, so the offshore balance at any moment is an amount the business could afford to dispute.

Then unwind according to the terms. Give notice as written, pursue settlement and reserve release dates in writing, and keep the file of the entire exchange — for the funds, and because the next diligence process will ask. What the exit is not is dramatic. No public repudiation, no payments stopped mid-flight, and no second offshore arrangement recommended by the first. The objective is a clean ledger and a one-paragraph history. Both are entirely achievable, which is more than can be said of the arrangement itself.

What is the position, and the sector's interest?

The position, flagged as this site's opinion and held without difficulty: no GPhC-registered pharmacy should hold an offshore brokered acquiring relationship. And the existence of a layer marketing them to pharmacy specifically is a fact the sector should regard as against its interests.

The wider interest goes further, returning to the impostor tax. The broker layer is part of the financial infrastructure that keeps the illegitimate market liquid. Every legitimate operator pays elevated costs because that market exists. The sector therefore has a direct commercial interest, alongside the obvious ethical one, in the layer being starved of business, reported where reporting routes exist and, above all, not supplied with respectable customers whose presence improves the portfolio's appearance.

The payments cluster concludes where it began. In a category priced on trust, the strongest position available to a pharmacy is being demonstrably and verifiably genuine. Every structure described in this article exists to serve businesses that are not. Decline it for precisely that reason.

Key takeaways

FAQs